Oral Yokukansan treatment for essential blepharospasm

Oral Yokukansan treatment for essential blepharospasm - Yokukansan for blepharospasm

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014084

Enrollment

Registered

2014-05-31

Start date

2014-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential blepharospasm

Interventions

Yokukansan 2.5g x 3/day for 1 month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged > 20 years.

Exclusion criteria

Exclusion criteria: Patients who undergo botulinum toxin injection within 3 months. Poor in health. Patients who take a medicine containing licorice or glycyrrhizic acid.

Design outcomes

Primary

Measure	Time frame
Grading scale reported by Jankovic National Eye Institute Visual Functioning Questionnaire 25 Severity of dry eye Evaluation before and 1 month after the start of treatment.	—

Secondary

Measure	Time frame
Blood test (potassium, Creatinine kinase, liver function) Evaluation before and 1 month after the start of treatment.	—

Countries

Japan

Contacts

Public ContactYasuhiro Takahashi

Aichi medical University Ophthalmology

yasuhiro_tak@yahoo.co.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026